SGLT2 Inhibitor Initiation in Heart Failure
Sodium-glucose cotransporter 2 inhibitors reduce heart failure admission and cardiovascular death in heart failure across the range of ejection fraction, with or without diabetes, and slow the decline in kidney function. Dapagliflozin and empagliflozin are used at a fixed dose with no titration. Start in hospital once stable or as an outpatient, when eGFR is 20 mL/min/1.73 m2 or over.
Counselling. Warn about genital mycotic infection, volume depletion, urinary infection and ketoacidosis, and teach sick day rules.
Diabetes. Glucose lowering is modest at low eGFR, but the heart failure benefit remains.













